Abstract | OBJECTIVE: MATERIALS AND METHODS:
Spinal cord ischemia was induced in normothermia for 14 min in Sprague-Dawley rats using direct aortic arch plus left subclavian artery cross-clamping through a limited thoracotomy. Experimental groups were as follows: sham-operation (n=15), control (n=15) receiving only vehicle, riluzole (n=15) receiving riluzole (4 mg/kg) before clamping and at the onset of reperfusion. Separate animals were used for monitoring physiologic parameters in the sham-operation (n=3), control (n=5), and riluzole (n=5) groups. Neurologic status was assessed at 6, 24 h, and then daily up to 96 h. Rats were randomly killed at 24, 48, or 96 h (n=5 for each time). Spinal cords were harvested for histopathology, immunohistochemistry for microtubule-associated protein 2 (MAP-2), TUNEL staining, and analysis of DNA fragmentation by agarose gel electrophoresis. RESULTS: All sham-operated rats had a normal neurologic outcome, whereas all control rats suffered severe and definitive paraplegia. Riluzole-treated rats had significantly better neurologic function compared to the control. Histopathology disclosed severe neuronal necrosis in the lumbar gray matter of control rats, whereas riluzole-treated rats suffered usually mild to moderate injury. Riluzole particularly prevented motor neurons injury. MAP-2 immunoreactivity was completely lost in control rats, whereas it was preserved either completely or partly in riluzole-treated rats. TUNEL staining revealed numerous apoptotic neurons scattered within the whole gray matter of control rats. Riluzole prevented or dramatically attenuated apoptotic neuronal death in treated rats. DNA extracted from lumbar spinal cords of sham-operated and riluzole-treated rats exhibited no laddering, whereas spinal cords from control rats showed DNA laddering with fragmentation into approximately 180 multiples of base pairs. CONCLUSIONS:
Riluzole may protect the spinal cord in a setting of severe ischemia by preventing neuronal necrosis and apoptosis. This drug may therefore be considered for clinical use during 'high risk' surgical procedures on the thoracoabdominal aorta.
|
Authors | L Lang-Lazdunski, C Heurteaux, A Mignon, J Mantz, C Widmann, J Desmonts, M Lazdunski |
Journal | European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
(Eur J Cardiothorac Surg)
Vol. 18
Issue 2
Pg. 174-81
(Aug 2000)
ISSN: 1010-7940 [Print] Germany |
PMID | 10925226
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Biomarkers
- Excitatory Amino Acid Antagonists
- Microtubule-Associated Proteins
- Riluzole
|
Topics |
- Animals
- Aorta, Thoracic
(surgery)
- Apoptosis
(drug effects)
- Biomarkers
- Electrophoresis, Agar Gel
- Excitatory Amino Acid Antagonists
(therapeutic use)
- In Situ Nick-End Labeling
- Ligation
(adverse effects)
- Male
- Microtubule-Associated Proteins
(metabolism)
- Necrosis
- Neurons
(metabolism, pathology)
- Rats
- Rats, Sprague-Dawley
- Riluzole
(therapeutic use)
- Spinal Cord
(metabolism, pathology)
- Spinal Cord Ischemia
(etiology, metabolism, pathology, prevention & control)
|